The aim of Journal of Translational Biotechnology is to provide a forum for the important advances in the discipline, enhancing their visibility by means of opinion and news articles, and providing overviews of the state of the art in each field through topic-, disease- or technology-focused review articles. Journal of Translational Biotechnology publishes new concepts in technology/methodology of relevance to the biological, biomedical, biotechnology as well as covers the commercial, political, ethical, legal, and societal aspects of this research. The core areas in which we are actively seeking research papers include: molecular engineering of nucleic acids and proteins; molecular therapy (therapeutics genes, antisense, siRNAs, aptamers, DNAzymes, ribozymes, peptides, proteins); large-scale biology (genomics, functional genomics, proteomics, structural genomics, metabolomics, etc.); computational biology (algorithms and modeling), regenerative medicine (stem cells, tissue engineering, biomaterials); imaging technology; analytical biotechnology (sensors/detectors for analytes/macromolecules), applied immunology (antibody engineering, xenotransplantation, T-cell therapies); precision biotechnology and medicine (Biomarkers, population study, treatment tolerance).

Journal of Translational Biotechnology also publishes news, and commentary to understand and bridge the gap among the laboratory, clinic, and biotechnology industries. Papers in the journal are rigorously peer-reviewed.